Evercore ISI analyst Cory Kasimov raised the firm’s price target on Moderna (MRNA) to $35 from $28 and keeps an In Line rating on the shares. The firm updated its estimates following the company’s Q4 report, telling investors that disciplined execution combined with the rapid pace of development in oncology may “flip-the-script” in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA: